In the treatment of SMA in neonates and infants, switching between SMN2-modifying drugs (nusinersen or risdiplam) and a gene therapy drug (onasemnogene abeparvovec) is a major issue. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.